Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL2373 Target Snapshot

C5a anaphylatoxin chemotactic receptor 1 · SINGLE PROTEIN · Homo sapiens

Back to Search Search this target Browse approvals Evidence Card
1,871Compounds
137Assays
1Approved Drugs
1,536.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Research home Demo workspace
Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-14

C5a anaphylatoxin chemotactic receptor 1 shows approved-linked disease relevance led by anti-neutrophil antibody associated vasculitis. 5 more disease programs remain visible in the same review block. 1 linked drug keeps the current disease frame grounded. Protein identity stays anchored to UniProt P21730. Start with anti-neutrophil antibody associated vasculitis, then reuse UniProt P21730 as the stable protein anchor across project notes and exports.

Review focus
Review-ready target frame

Start with anti-neutrophil antibody associated vasculitis, then reuse UniProt P21730 as the stable protein anchor across project notes and exports.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-14 1 linked drug
Open source guide
Disease program
anti-neutrophil antibody associated vasculitis

C5a anaphylatoxin chemotactic receptor 1 shows approved-linked disease relevance led by anti-neutrophil antibody associated vasculitis. 5 more disease programs remain visible in the same review block. 1 linked drug remains visible in the same block.

Start review with anti-neutrophil antibody associated vasculitis because it currently carries approved-linked support. Linked drugs include AVACOPAN. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Disease source · ChEMBL drug mechanism + indication proxy
Approved-linked Open Targets-ready proxy 1 linked drug
Open disease block
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats C5a anaphylatoxin chemotactic receptor 1 as ChEMBL target CHEMBL2373, mapped to UniProt P21730. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
C5a anaphylatoxin chemotactic receptor 1
SINGLE PROTEIN · Homo sapiens
As of 2026-09-14
ChEMBL target ID
CHEMBL2373
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-14
www.ebi.ac.uk
UniProt accession
P21730
C5a anaphylatoxin chemotactic receptor 1
UniProt accession via ChEMBL component mapping As of 2026-09-14
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-14
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether C5a anaphylatoxin chemotactic receptor 1 is the right protein anchor across sources, using UniProt P21730 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need to confirm why anti-neutrophil antibody associated vasculitis is currently framed as approved-linked support. It currently carries 1 linked drug in the same disease frame.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

Preferred NameC5a anaphylatoxin chemotactic receptor 1
Target TypeSINGLE PROTEIN
OrganismHomo sapiens
UniProtP21730
ChEMBL ↗ UniProt ↗ NCBI Protein ↗

Next Actions

SearchRun a focused querySearch the database using this target name as the starting context. ApprovalsCheck approved moleculesSee which approved drugs connect back to this target and its surrounding signal space. FeedScan papers & updatesStay in the project thread while checking recent papers and platform updates.
UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelC5a anaphylatoxin chemotactic receptor 1
UniProt AccessionP21730
Component TypeProtein
Sequence Length350 aa

C5a anaphylatoxin chemotactic receptor 1

Source · UniProt accession via ChEMBL component mapping
UniProt Context ↗
Review Cue

How to read this target

Review this target as C5a anaphylatoxin chemotactic receptor 1, mapped to UniProt P21730. Sequence length is 350 aa.

Mapped IDP21730
Review nameC5a anaphylatoxin chemotactic receptor 1
OrganismHomo sapiens
Disease Relevance

Disease Relevance & Evidence Level

Open Targets-ready disease context using the current target-indication evidence contract.

Approved-linked Open Targets-ready proxy

C5a anaphylatoxin chemotactic receptor 1 shows approved-linked disease relevance led by anti-neutrophil antibody associated vasculitis. 5 more disease programs remain visible in the same review block.

Approved-linked Approved
anti-neutrophil antibody associated vasculitis
1 linked drug · 1 direct · 1 efficacy
Linked drugAVACOPAN
Approved-linked Approved
anti-neutrophil cytoplasmic antibody-associated vasculitis
1 linked drug · 1 direct · 1 efficacy
Linked drugAVACOPAN
Approved-linked Approved
Granulomatosis with Polyangiitis
1 linked drug · 1 direct · 1 efficacy
Linked drugAVACOPAN
Approved-linked Approved
microscopic polyangiitis
1 linked drug · 1 direct · 1 efficacy
Linked drugAVACOPAN
Late clinical Phase III
vasculitis
1 linked drug · 1 direct · 1 efficacy
Linked drugAVACOPAN
Clinical signal Phase II
atypical hemolytic-uremic syndrome
1 linked drug · 1 direct · 1 efficacy
Linked drugAVACOPAN
Source · ChEMBL drug mechanism + indication proxy
ChEMBL target record ↗
Review Cue

How to read disease relevance

Start review with anti-neutrophil antibody associated vasculitis because it currently carries approved-linked support. Linked drugs include AVACOPAN. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Lead diseaseanti-neutrophil antibody associated vasculitis
Strongest levelApproved-linked
Block modeOpen Targets-ready proxy
Clinical Profile

Clinical Phase Distribution

1
Approved
Assay Mix

Activity Type Distribution

IC501,365.0
KI86.0
EC5080.0
KD5.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL3646938 9.3 IC50 0.5 Preclinical
CHEMBL3646964 9.3 IC50 0.5 Preclinical
CHEMBL3646934 9.0 IC50 1.0 Preclinical
CHEMBL3646944 9.0 IC50 1.0 Preclinical
CHEMBL3646945 9.0 IC50 1.0 Preclinical
CHEMBL3646951 9.0 IC50 1.0 Preclinical
CHEMBL3646952 9.0 IC50 1.0 Preclinical
CHEMBL3646953 9.0 IC50 1.0 Preclinical
CHEMBL3646956 9.0 IC50 1.0 Preclinical
CHEMBL3646957 9.0 IC50 1.0 Preclinical
Distribution

pChEMBL Value Distribution

68
5.0
78
5.5
98
6.0
183
6.5
109
7.0
298
7.5
46
8.0
27
8.5
26
9.0
0
9.5
pChEMBL
Approved Drugs

Approved Drugs

LOPERAMIDE HYDROCHLORIDE
CHEMBL1707
Approved 1976
Properties Compare Identifier
Assay Landscape

Assay Landscape

137
Total Assays
558
Tested Compounds
2
Assay Types
Binding — 79 assays, 558 compounds
BAO Format Assays Compounds Avg pChEMBL
assay format 25 376 7.0
single protein format 25 41 5.7
cell-based format 20 137 6.7
tissue-based format 6 1 7.8
cell membrane format 3 3 —
Functional — 58 assays, 385 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 35 214 6.6
assay format 21 171 7.6
tissue-based format 2 0 —

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine